Dow climbs 530 points as investors gear up for earnings season

• US stock indexes rose on Monday as investors prepared for upcoming earnings reports, which will provide details around the impact of coronavirus on companies.
• PepsiCo gained after revealing better-than-expected sales to kick off earnings season.
• Pfizer and BioNTech gained jumped after two of the firms' COVID vaccine candidates received "fast track" status from the FDA.
• Oil fell amid fears of OPEC+ unwinding production curbs. West Texas Intermediate crude dropped as much as 2.2%, to $39.66 per barrel.
• Watch major indexes update live here.

US equities gained on Monday as investors prepared for earnings reports that will show the degree of damage imposed by the coronavirus.

PepsiCo jumped in early trading after revealing better-than-expected revenue in the second quarter. The report marked the unofficial start of an earnings season set to be more chaotic than usual.

Several companies pulled forward guidance in their previous reports, citing uncertainties sourced from the coronavirus pandemic. Investors now wait to see which corporate giants outperformed and which faltered throughout widespread lockdowns.

Here's where US indexes stood at 1:20 p.m. ET market open on Monday:

• S&P 500: 3,232.47, up 1.5%
• Dow Jones industrial average: 26,608.41, up 2.1% (539 points)
• Nasdaq composite: 10,790.63, up 1.6%

Read more: UBS says buy these 18 diamond-in-the-rough stocks that will offer massive gains over multiple years, even as their underlying industries suffer

Major banks kick off earnings season on Tuesday, with JPMorgan, Citigroup, and Wells Fargo all slated to release quarterly metrics. The firms are expected to show a sharp decline in profits due to bolstered loan-loss reserves and weakened net interest income.

In deal news, Maxim Integrated Products leaped after rival firm Analog Devices said it would purchase the firm in a $21 billion all-stock deal. The takeover is among the year's largest.

Pfizer and BioNTech gained after two of the firms' coronavirus vaccine candidates received "fast track" status from the Food and Drug Administration. Both companies have said they plan to produce as many as 100 million doses by the end of 2020 if their vaccine gains regulatory approval. A trial with up to 30,000 participants can begin as soon as later this month, they added.

Read more: BlackRock's bond chief who oversees $2.3 trillion told us how the coronavirus crisis created a game-changing investment opportunity for the first time in almost 20 years — and shared 4 ways he's cashing in

Oil declined amid fears of OPEC+ retracing production cuts in its Wednesday meeting. West Texas Intermediate crude slid as much as 2.2%, to $39.66 per barrel. Brent crude, the international benchmark, fell 2%, to $42.39 per barrel, at intraday lows.

The stock market's gains follow a positive close to the previous week. Equities climbed roughly 1% on Friday as investors cheered a different coronavirus vaccine candidate. Gilead Sciences announced trial data for its remdesivir compound found a 62% reduction to mortality risk among severe COVID patients. Banks including Goldman Sachs, Wells Fargo, and Citigroup also jumped through the session.

Now read more markets coverage from Markets Insider and Business Insider:

A Wall Street expert sees a retail-investing trend that preceded the dot-com bubble and financial crisis bubbling up again — and warns it will end 'abruptly and painfully' for the stock market

'High returns with low risk': Why wildly unpredictable economic data is a reason to buy stocks, according to one Wall Street chief strategist

Wall Street is being shaken to its core by a legion of Gen Z day traders. From a casual hobbyist to a 20-year-old running a 14,000-person platform, meet the new generation of retail investors.